MedTrace Logo

A Study of QBI-139 in Subjects With Advanced Solid Tumors

NCT00818831 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-01-28

No results posted yet for this study

Summary

The purposes of this trial are:

* To evaluate the toxicity and tolerability of QBI-139 in patients with advanced refractory solid tumors.
* To determine the maximum tolerated dose of QBI-139 in patients with advanced, refractory solid tumors.

Patients will receive QBI-139 by IV infusion over at least one hour once weekly for three weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3 to 6 patients receive escalating doses of QBI-139 until the maximum tolerated dose (MTD) is determined.

Conditions

Interventions

DRUG

QBI-139

QBI-139 is being administered once a week over a two hour infusion in escalating doses.

Sponsors & Collaborators

  • Quintessence Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00818831 on ClinicalTrials.gov